Venous Thromboembolism Treatment and Prophylaxis

Direct Oral Anticoagulants for VTE Treatment and Prophylaxis

• The American College of Chest Physicians recommends direct oral anticoagulants (DOACs) including rivaroxaban and apixaban for VTE treatment and prophylaxis 1, 2
• The International Society on Thrombosis and Haemostasis supports the use of apixaban 2.5 mg twice daily for primary VTE prevention in ambulatory cancer patients, as evaluated in the AVERT trial 3
• The American College of Chest Physicians suggests that DOACs may be considered for antiphospholipid syndrome treatment, as an alternative to warfarin 1